Twinlab Reports $9.5 Million Net Loss for Fiscal Year 2024, Implements Restructuring Efforts

Twinlab Consolidated Holdings, Inc. reported a net loss of $9.5 million for the fiscal year ending December 31, 2024, a significant improvement compared to a net loss of $13.7 million in the previous year. The company's total revenue decreased by 14% to $11.7 million, down from $13.6 million in 2023, primarily due to production backlogs and reduced demand from major customers. Gross profit also fell by 22% to $3.9 million, attributed to increased product input costs. The company’s operating loss widened to $1.8 million from $1.4 million in 2023, reflecting ongoing challenges in managing costs and sales.

In terms of operational changes, Twinlab has undertaken significant restructuring efforts, including the cessation of operations for its NutraScience Labs subsidiary, which was officially discontinued in 2023. This decision was part of a broader strategy to streamline operations and reduce costs amid ongoing liquidity constraints. The company has also surrendered multiple leased office spaces, resulting in impairment losses and further financial strain. As of December 31, 2024, Twinlab reported total liabilities of $154.5 million, an increase from $148 million in the previous year, largely due to accrued interest and current liabilities related to discontinued operations.

The company’s customer concentration remains high, with the top three customers accounting for approximately 53% of total sales in 2024, up from 32% in 2023. This reliance on a limited customer base raises concerns about revenue stability. Additionally, accounts receivable from these customers represented 62% of total accounts receivable as of December 31, 2024. Twinlab's employee count has decreased to seven full-time employees, down from eight in the previous year, reflecting the company's efforts to reduce operational costs.

Looking ahead, Twinlab's management has expressed uncertainty regarding the company's ability to continue as a going concern, citing substantial accumulated deficits and ongoing liquidity challenges. The company is exploring various strategic alternatives, including potential settlements, capital raising, and restructuring options. However, there is no assurance that these efforts will be successful. The financial statements for 2024 have been prepared on a going concern basis, indicating that the company may need additional funding to support its operations in the coming year.